Canadian JAMP Pharma Group Gets Involved - Donating one million doses of hydroxychloroquine to hospitals to help combat COVID-19

BOUCHERVILLE, QC, March 23, 2020 /CNW Telbec/ - JAMP Pharma Group, a Canadian pharmaceutical company, announced today that it is donating one million doses of hydroxychloroquine to Canadian hospitals, a drug that is normally used to treat malaria and rheumatoid arthritis and which could potentially be useful in treating hospitalized patients infected with the COVID-19 virus.

With more than 1,300 reported cases of infection in Canada and health professionals from coast to coast mobilized in the battle against COVID-19, Boucherville-based JAMP, a leader in the pharmaceutical industry, wants to do its part and to help Canadian healthcare workers battle this pandemic crisis.

Promising preliminary studies
Scientists, doctors and researchers the world over are working tirelessly to develop a vaccine against the virus. Until they do, considerable effort is being made to find effective treatments for COVID-19 and, while treatments are still being studied, it appears that preliminary results¹ of hydroxycholoroquine in patients who've contracted the virus have caught the attention of those experts.

"JAMP Pharma Group is pleased to contribute to the collective efforts of governments and health partners in the attempt to contain the effects of COVID-19. Solidarity and mutual aid are precious assets in times of crisis. We have a duty to do everything in our power to help Canadians through this," said Louis Pilon, President/CEO of JAMP Pharma Group.

The company is already in touch with many healthcare stakeholders who are managing this crisis to offer its collaboration. On Monday, March 23, the company will be in contact with concerned stakeholders on how to best distribute these hydroxychloroquine doses to hospitals.

Combatting shortages
The purpose of this generous donation to Canadian hospitals is twofold: JAMP Pharma Group wants to maximize the availability of the drug to the country's health establishments for hospitalized patients who have contracted COVID-19, but also wants to avoid a shortage of the medication for persons using or needing hydroxychloroquine to treat the diseases for which the medication was approved by Health Canada.

JAMP Pharma Group will continue to supply distributors and drugstore chains for patients who already depend on the company for the medication.

About JAMP Pharma Group
JAMP Pharma Group is a privately owned Canadian company headquartered in the Montreal region. Having enjoyed remarkable growth over the past 10 years, JAMP Pharma Group owns a portfolio of more than 260 molecules and is a leading player in the generic pharmaceutical industry in Canada for the launch of new products, according to Health Canada approvals from January to December 2019. It is also one of the leaders in Canada among companies with the highest volume of annual prescriptions, according to IQVIA. The company also has its Wampole division with more than 160 over-the-counter products that range from vitamins and supplements to natural products as well as prescription medications with its Orimed Pharma company.

SOURCE JAMP Pharma Corporation

or media requests: Véronique Blais, TACT, 514-241-2686